Clinical Trial

A Study to Investigate Safety, Tolerability and Pharmacokinetics of REM0045392 Compared With Placebo in Healthy Participants.

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
This study is testing if the medicine REM0045392 is safe and well-tolerated. It also looks at whether food affects how the medicine works. The medicine will be tested in Healthy men (Part 1 and 2) and Healthy Older men and women (Part 3). Participants will take the medicine once (in Part 1) or during 14 days (in Part 2 and 3), with increasing doses. REM0045392 is being developed as a treatment for Alzheimer's disease.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-04; most recent amendment 2026-02-02.
Status change: Recruiting → Terminated 2026-02-02
Status change: Active, Not Recruiting → Recruiting 2025-11-25
Trial Details
NCT Number NCT07016464
Lead Sponsor reMYND
Conditions Healthy
Enrollment 19 participants
Start Date 2025-03-20
Primary Completion 2025-06-23 (estimated)
Study Completion 2025-06-23 (estimated)
Updated on ClinicalTrials.gov 2026-02-04